COMMUNIQUÉS West-GlobeNewswire

ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

16/11/2017 - 07:02

REGULATED INFORMATION Positive Phase III results with caplacizumab and a successful U.S. IPO GHENT, Belgium, 16 November 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced its non-audited financial [...]

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

16/11/2017 - 07:01

PRESS RELEASE TiGenix announces approval of trade name for lead development candidate Cx601 in Europe International Nonproprietary Name (INN), darvadstrocel, approved for Cx601 Leuven (BELGIUM) - November 16, 2017, 7h: [...]

TiGenix annonce l'approbation d'un nom commercial en Europe pour son produit candidat en phase de développement, le Cx601

16/11/2017 - 07:01

COMMUNIQUÉ DE PRESSE TiGenix annonce l'approbation d'un nom commercial en Europe pour son produit candidat en phase de développement, le Cx601 Darvadstrocel est la dénomination commune internationale (DCI) approuvée [...]

Orphazyme announces the result of its IPO, including an offer price of DKK 80 per share

16/11/2017 - 06:31

Company announcement Orphazyme A/S No. 5/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 16 November 2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN [...]

Orphazyme A/S: Election of new members of the Board of Directors

16/11/2017 - 06:16

Company announcement Orphazyme A/S No. 4/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 16 November 2017 On 16 November 2017, Orphazyme A/S ("Orphazyme") held an [...]

Arsanis Announces Pricing of Initial Public Offering

16/11/2017 - 05:20

WALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious [...]

Achillion Announces Pricing of Secondary Offering Of Common Stock

16/11/2017 - 04:05

NEW HAVEN, Conn., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (“Achillion”) (NASDAQ: ACHN ) today announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock [...]

Loop Industries provides update on the Montreal facility

15/11/2017 - 22:45

MONTREAL, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Loop Industries, Inc. (OTCQX:LLPP), a leader in sustainably produced polyethylene terephthalate (Polyester/PET) resin, announced today that following its due diligence review [...]

AxoGen, Inc. Announces Proposed Public Offering of Common Stock

15/11/2017 - 22:43

ALACHUA, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it [...]

EDAP TMS Reports Third Quarter 2017 Results

15/11/2017 - 22:30

EDAP TMS Reports Third Quarter 2017 Results EDAP's HIFU patient treatment revenues grew 29% compared to third quarter 2016. EDAP received FDA clearance for its Ablatherm Fusion ® late in the quarter. EDAP's cash [...]

MacroGenics Names Dr. Jay Siegel to its Board of Directors

15/11/2017 - 22:30

ROCKVILLE, MD, Nov. 15, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]

Allscripts to deliver anaesthesiology solution at the Royal Adelaide Hospital

15/11/2017 - 22:30

ADELAIDE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX ) has been appointed by South Australia Health to deliver its anaesthesia information management system (AIMS) at the Royal Adelaide [...]

Allscripts to deliver anesthesiology solution at the Royal Adelaide Hospital

15/11/2017 - 22:30

ADELAIDE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX ) has been appointed by South Australia Health to deliver its anesthesia information management system (AIMS) at the Royal Adelaide [...]

Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial

15/11/2017 - 22:30

Low Dose of Inarigivir Soproxil (50mg) Monotherapy Demonstrates a Favorable Safety Profile and Significant Dose-Dependent Antiviral Activity, Meeting Both Primary Endpoints Conference Call Scheduled for Tomorrow, Nov. [...]

K2M Group Holdings, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference

15/11/2017 - 22:05

LEESBURG, Va., Nov. 15, 2017 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ: KTWO ) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three- [...]

BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer

15/11/2017 - 22:01

JERUSALEM, Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE: BICL ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, [...]

Adverum Biotechnologies to Present at Upcoming Conferences

15/11/2017 - 22:01

MENLO PARK, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM ), a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that [...]

Nuvectra to Present at the 29th Annual Piper Jaffray Healthcare Conference

15/11/2017 - 22:01

PLANO, Texas, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR ), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief [...]

Articles of Association for Genmab A/S

15/11/2017 - 21:40

Genmab A/S has published its Articles of Association dated November 14, 2017. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel Curtis Gravesen, Senior Vice [...]